文献速递免疫规划卫生政策与健康促进

澳大利亚针对年轻男男性行为者的人乳头瘤病毒靶向疫苗接种可产生显著人群获益且具成本效益

Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective.
PubMed 文献 · Vaccine · 2017-08-05

研究构建模型预测2017—2036年澳大利亚19万男男性行为者(MSM)中人乳头瘤病毒(HPV)流行轨迹,比较男孩常规接种、仅年轻MSM靶向接种及二者联合三种情景。仅靶向年轻MSM每年覆盖20%可预防肛生殖器疣和肛癌带病生存人年但仅稳定肛癌发病率;男孩接种覆盖约84%可使年轻MSM低危和高危HPV分别于2024年和2032年减少90%。在男孩接种基础上增加年轻MSM靶向补种每获得一个质量调整生命年额外花费6788澳元,及时实施具成本效益。

要点

  • 仅靶向年轻MSM接种每年覆盖20%可预防肛生殖器疣但仅稳定肛癌发病率。
  • 男孩接种覆盖约84%可使年轻MSM低危和高危HPV分别于2024年和2032年减少90%。
  • 男孩接种基础上联合年轻MSM补种每QALY额外花费6788澳元,延迟实施降低成本效益。

核心结论

  • 男孩接种覆盖约84%可使HPV减少90%;年轻MSM靶向接种若及时实施具成本效益。

研究设计与样本

  • 构建 compartmental 模型,预测2017—2036年澳大利亚19万MSM中HPV流行轨迹,比较男孩接种、仅年轻MSM(15—26岁)靶向接种及二者联合三种情景。

主要发现

  • 仅靶向年轻MSM每年覆盖20%且无男孩接种,2017—2036年预防49,283例(31,253—71,500)肛生殖器疣和191人年(88—319)肛癌带病生存,但仅稳定肛癌发病率。
  • 男孩接种2017—2036年预防82,056例(52,100—117,164)肛生殖器疣和447人年(204—725)肛癌带病生存,肛癌发病率大幅下降,但需≥84%男孩接种。
  • 在男孩接种基础上增加年轻MSM靶向接种,额外预防14,912例(8479—21,803)肛生殖器疣和91人年(42—152)肛癌带病生存。
  • 与男孩接种联合时,年轻MSM补种每获得一个QALY额外花费6788澳元(4628—11,989),延迟实施降低其成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the effectiveness and cost-effectiveness of a targeted human papillomavirus (HPV) vaccination program for young (15-26) men who have sex with men (MSM). METHODS: We developed a compartmental model to project HPV epidemic trajectories in MSM for three vaccination scenarios: a boys program, a targeted program for young MSM only and the combination of the two over 2017-2036. We assessed the gain in quality-adjusted-life-years (QALY) in 190,000 Australian MSM. RESULTS: A targeted program for young MSM only that achieved 20% coverage per year, without a boys program, will prevent 49,283 (31,253-71,500) cases of anogenital warts, 191 (88-319) person-years living with anal cancer through 2017-2036 but will only stablise anal cancer incidence. In contrast, a boys program will prevent 82,056 (52,100-117,164) cases of anogenital warts, 447 (204-725) person-years living with anal cancers through 2017-2036 and see major declines in anal cancer. This can reduce 90% low- and high-risk HPV in young MSM by 2024 and 2032, respectively, but will require vaccinating ≥84% of boys. Adding a targeted program for young MSM to an existing boys program would prevent an additional 14,912 (8479-21,803) anogenital wart and 91 (42-152) person-years living with anal cancer. In combination with a boys' program, a catch-up program for young MSM will cost an additional $AUD 6788 ($4628-11,989) per QALY gained, but delaying its implementation reduced its cost-effectiveness. CONCLUSIONS: A boys program that achieved coverage of about 84% will result in a 90% reduction in HPV. A targeted program for young MSM is cost-effective if timely implemented.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang L, Regan DG, Ong JJ, et al. Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. Vaccine. 2017. PMID: 28789853. doi:10.1016/j.vaccine.2017.07.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。